Actuate Therapeutics, Inc. received a notice from Nasdaq regarding its failure to meet the minimum Market Value of Listed Securities (MVLS) requirement of $50 million. The company has until January 11, 2027, to regain compliance with the MVLS requirement to avoid potential delisting from the Nasdaq Global Market. Actuate Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions.
